Major advances in managing community-acquired pneumonia

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Khan, Waseem Asrar ^a   Woodhead, Mark ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; BENZODIAZEPINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; LEVOFLOXACIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G DERIVATIVE; PREDNISOLONE; PROADRENOMEDULLIN; PROCALCITONIN;

AMERICAN THORACIC SOCIETY INFECTIOUS DISEASES SOCIETY OF AMERICA SEVERITY CRITERIA; ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDIA; COMMUNITY ACQUIRED PNEUMONIA; CORONAVIRUS INFECTION; COXIELLA BURNETII; CRB65 SCORE; CURB65 SCORE; DISEASE SEVERITY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTENSIVE CARE UNIT; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; MYCOPLASMA PNEUMONIAE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTPATIENT; PNEUMONIA; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; RESPIRATORY VIRUS; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; SPAIN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE COUNT; VIRUS PNEUMONIA;

EID: 84885578343     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-43     Document Type: Article

References (38)

1. Seminog OO, Goldacre MJ: Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax 2013, 68:171-6.
2. Obiora E, Hubbard R, Sanders RD, Myles PR: The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013, 68:163-70.
3. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J: Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012, 345:e4260.
4. Capelastegui, et al.: Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes BMC Infectious Diseases 2012, 12:134.
5. Cillóniz C, Ewig S, Polverino E, Marcos MA, Prina E, Sellares J, Ferrer M, Ortega M, Gabarrús A, Mensa J, Torres A: Communityacquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012, 40:931-8.
6. Choi S, Hong S, Ko G, Lee Y, Park HJ, Park S, Moon SM, Cho O, Park K, Chong YP, Kim S, Huh JW, Sung H, Do K, Lee S, Kim M, Jeong J, Lim C, Kim YS, Woo JH, Koh Y: Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012, 186:325-32.
7. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-20.
8. Cillóniz C, Ewig S, Menéndez R, Ferrer M, Polverino E, Reyes S, Gabarrús A, Marcos MA, Cordoba J, Mensa J, Torres A: Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 2012, 65:223-30.
9. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, et al.: Human infection with a novel avianorigin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-97.
10. Parry J: H7N9 avian flu kills seven and infects 23 in China. BMJ 2013, 346:f2222.
11. Chalmers JD, et al.: Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis Intensive Care Med (2011) 37:1409-1420
12. Thorax 2013, 68:39-47.
13. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT: Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011, 66:416-23.
14. Francis NA, et al.: Severity assessment for lower respiratory tract infections: Potential use and validity of CRB-65 in primary care Primary Care Respiratory Journal 2012 Mar;21(1): 65-70.
15. Ewig S, Bauer T, Richter K, Szenscenyi J, Heller G, Strauss R, Welte T: Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2013, 41:917-22.
16. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A: Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012, 16: R141.
17. Lepper PM, Ott S, Nüesch E, Eynatten M von, Schumann C, Pletz MW, Mealing NM, Welte T, Bauer TT, Suttorp N, Jüni P, Bals R, Rohde G: Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012, 344:e3397.
18. Berg P, Lindhardt BØ: The role of procalcitonin in adult patients with community-acquired pneumonia-a systematic review. Dan Med J 2012, 59:A4357.
19. España PP, Capelastegui A, Bilbao A, Diez R, Izquierdo F, Lopez de Goicoetxea MJ, Gamazo J, Medel F, Salgado J, Gorostiaga I, Quintana JM: Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012, 31:3397-405.
20. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kühn F, Bassetti S, Sprenger M, Bachli E, Sigrist T, Schwietert M, Amin D, Hausfater P, Carre E, Gaillat J, Schuetz P, Regez K, Bossart R, Schild U, Mueller B: Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012, 172:715-22.
21. Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, Pablo F de, Ferrer M, Menendez R, Torres A: Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012, 39:1144-55.
22. Courtais C, Kuster N, Dupuy A, Folschveiller M, Jreige R, Bargnoux A, Guiot J, Lefebvre S, Cristol J, Sebbane M: Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2013, 31:215-21.
23. Zobel K, Martus P, Pletz MW, Ewig S, Prediger M, Welte T, Bühling F: Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network community-acquired pneumoniaNETZ. BMC Pulm Med 2012, 12:6.
24. Kolditz M, Höffken G, Martus P, Rohde G, Schütte H, Bals R, Suttorp N, Pletz MW: Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012, 12:90.
25. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA: BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl 3):iii1-55.
26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72. (Pubitemid 46290553)
27. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJM: Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17(Suppl 6): E1-59.
28. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR: Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review andmeta-analysis. Clin Infect Dis 2012, 55:371-80.
29. Menéndez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín-Villasclaras JJ, Bello S, Alfageme I, Castro FR de, Rello J, Molinos L, Ruiz-Manzano J: Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012, 39:156-62.
30. Paul M, et al.: The need for macrolides in hospitalised communityacquired pneumonia: propensity analysis Eur Respir J 2007; 30:525-531. (Pubitemid 351182077)
31. Rodrigo C, Mckeever TM, Woodhead M, Lim WS: Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013, 68:493-5.
32. Snijders D, Daniels JMA, Graaff CS de, van der Werf TS, Boersma WG: Efficacy of corticosteroids in communityacquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010, 181:975-82.
33. Meijvis SCA, Hardeman H, Remmelts HHF, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EMW, Endeman H, Grutters JC, Bos WJW, Biesma DH: Dexamethasone and length of hospital stay in patients with communityacquired pneumonia: a randomised, double-blind, placebocontrolled trial. Lancet 2011, 377:2023-30.
34. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-8.
35. Wilson KC, Schünemann HJ: An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011, 183:1454-62.
36. Lee JS: Processes of Care and Outcomes for Community-Acquired Pneumonia The American Journal of Medicine (2011) 124:1175.
37. Sutton M, Nikolova S, Boaden R, Lester H, McDonald R, Roland M: Reduced mortality with hospital pay for performance in England. N Engl J Med 2012, 367:1821-8.
38. Carratalà J, Garcia-Vidal C, Ortega L, Fernández- Sabé N, Clemente M, Albero G, López M, Castellsagué X, Dorca J, Verdaguer R, Martínez-Montauti J, Manresa F, Gudiol F: Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired.